These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

461 related items for PubMed ID: 23395995

  • 1. Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Nakazawa T, Hidaka H, Takada J, Okuwaki Y, Tanaka Y, Watanabe M, Shibuya A, Minamino T, Kokubu S, Koizumi W.
    Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):683-9. PubMed ID: 23395995
    [Abstract] [Full Text] [Related]

  • 2. Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma.
    Kuzuya T, Asahina Y, Tsuchiya K, Tanaka K, Suzuki Y, Hoshioka T, Tamaki S, Kato T, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Izumi N.
    Oncology; 2011 Jun; 81(3-4):251-8. PubMed ID: 22116493
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
    Kawaoka T, Aikata H, Murakami E, Nakahara T, Naeshiro N, Tanaka M, Honda Y, Miyaki D, Nagaoki Y, Takaki S, Hiramatsu A, Waki K, Takahashi S, Chayama K.
    Oncology; 2012 Jun; 83(4):192-200. PubMed ID: 22890083
    [Abstract] [Full Text] [Related]

  • 4. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.
    Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL.
    Cancer; 2010 Oct 01; 116(19):4590-6. PubMed ID: 20572033
    [Abstract] [Full Text] [Related]

  • 5. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
    Yamamoto K, Imamura H, Matsuyama Y, Hasegawa K, Beck Y, Sugawara Y, Makuuchi M, Kokudo N.
    Ann Surg Oncol; 2009 Oct 01; 16(10):2795-804. PubMed ID: 19669841
    [Abstract] [Full Text] [Related]

  • 6. Clinical characteristics among patients with hepatocellular carcinoma according to the serum levels of alpha-fetoprotein and des-y-carboxy prothrombin.
    Dohmen K, Shigematsu H, Irie K, Ishibashi H.
    Hepatogastroenterology; 2003 Oct 01; 50(54):2072-8. PubMed ID: 14696467
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of response evaluation criteria in solid tumors and tumor markers.
    Miyaki D, Kawaoka T, Aikata H, Kan H, Fujino H, Fukuhara T, Kobayashi T, Naeshiro N, Honda Y, Tsuge M, Hiramatsu A, Imamura M, Hyogo H, Kawakami Y, Yoshimatsu R, Yamagami T, Awai K, Chayama K.
    J Gastroenterol Hepatol; 2015 Apr 01; 30(4):726-32. PubMed ID: 25311578
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.
    Aoyagi Y, Oguro M, Yanagi M, Mita Y, Suda T, Suzuki Y, Hata K, Ichii K, Asakura H.
    Cancer; 1996 May 01; 77(9):1781-6. PubMed ID: 8646674
    [Abstract] [Full Text] [Related]

  • 11. Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma.
    Lee MH, Kim SU, Kim DY, Ahn SH, Choi EH, Lee KH, Lee DY, Seong J, Han KH, Chon CY, Park JY.
    J Gastroenterol Hepatol; 2012 Feb 01; 27(2):313-22. PubMed ID: 21793906
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
    Kim HY, Park JW, Joo J, Kim H, Woo SM, Lee WJ, Kim CM.
    J Gastroenterol Hepatol; 2013 Nov 01; 28(11):1756-61. PubMed ID: 23800278
    [Abstract] [Full Text] [Related]

  • 14. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY, Paik YH, Lim HY, Kim YG, Lim HK, Min YW, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC.
    Liver Int; 2013 Jul 01; 33(6):950-7. PubMed ID: 23601249
    [Abstract] [Full Text] [Related]

  • 15. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma.
    Vora SR, Zheng H, Stadler ZK, Fuchs CS, Zhu AX.
    Oncologist; 2009 Jul 01; 14(7):717-25. PubMed ID: 19581525
    [Abstract] [Full Text] [Related]

  • 16. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib.
    Yau T, Yao TJ, Chan P, Wong H, Pang R, Fan ST, Poon RT.
    Oncologist; 2011 Jul 01; 16(9):1270-9. PubMed ID: 21885876
    [Abstract] [Full Text] [Related]

  • 17. A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma.
    Ertle JM, Heider D, Wichert M, Keller B, Kueper R, Hilgard P, Gerken G, Schlaak JF.
    Digestion; 2013 Jul 01; 87(2):121-31. PubMed ID: 23406785
    [Abstract] [Full Text] [Related]

  • 18. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC.
    Toyoda H, Kumada T, Kaneoka Y, Osaki Y, Kimura T, Arimoto A, Oka H, Yamazaki O, Manabe T, Urano F, Chung H, Kudo M, Matsunaga T.
    J Hepatol; 2008 Aug 01; 49(2):223-32. PubMed ID: 18571271
    [Abstract] [Full Text] [Related]

  • 19. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size.
    Nakamura S, Nouso K, Sakaguchi K, Ito YM, Ohashi Y, Kobayashi Y, Toshikuni N, Tanaka H, Miyake Y, Matsumoto E, Shiratori Y.
    Am J Gastroenterol; 2006 Sep 01; 101(9):2038-43. PubMed ID: 16848811
    [Abstract] [Full Text] [Related]

  • 20. Clinical utility of des-γ-carboxyprothrombin kinetics as a complement to radiologic response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Park WH, Shim JH, Han SB, Won HJ, Shin YM, Kim KM, Lim YS, Lee HC.
    J Vasc Interv Radiol; 2012 Jul 01; 23(7):927-36. PubMed ID: 22633621
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.